AMPT

AMPT
Michael D. Turnbull · CC BY-SA 4.0 · source
Name	AMPT
IUPAC name	3-(2-Aminoethyl)phenylthiocyanate

AMPT

Introduction

AMPT is a small molecule historically studied in neurochemistry, psychopharmacology, and clinical research for its capacity to alter catecholamine metabolism. Investigations of AMPT intersect with work by Alden H. Miller, Arvid Carlsson, H. G. Snyder, Elliot Valenstein and institutions such as National Institutes of Health, Addenbrooke's Hospital, Massachusetts General Hospital and Karolinska Institutet. The compound has been evaluated alongside agents like reserpine, α-methyl-para-tyrosine, p-chlorophenylalanine and levodopa in studies involving disorders treated at centers such as Mayo Clinic and Johns Hopkins Hospital.

Chemical Properties and Synthesis

AMPT is characterized by a substituted aromatic scaffold bearing an aminoethyl side chain and a thiocyanate or related functional group depending on synthetic route variations reported in the chemical literature. Synthetic methods have been developed in organic chemistry laboratories associated with University of Cambridge, University of Oxford, Columbia University and industrial research divisions of DuPont and Pfizer. Typical routes adapt electrophilic aromatic substitution, nucleophilic substitution, and protection–deprotection strategies analogous to syntheses used for tyrosine hydroxylase inhibitors and catecholamine pathway analogs. Analytical characterization of AMPT preparations has employed techniques standardized by American Chemical Society guidelines, including nuclear magnetic resonance spectroscopy developed at Bell Labs, mass spectrometry pioneered at Scripps Research Institute, and infrared spectroscopy methodologies influenced by work at National Physical Laboratory.

Pharmacology and Mechanism of Action

Pharmacological activity of AMPT involves interference with catecholamine biosynthetic enzymes; in experimental contexts it is compared with agents targeting tyrosine hydroxylase and dopa decarboxylase pathways studied by researchers at Stanford University, Yale University and University of California, San Francisco. Mechanistic models cite reversible or competitive inhibition kinetics measured in vitro in assays derived from protocols used at Rockefeller University and Institut Pasteur. AMPT has been used as a biochemical probe in studies employing tracer methodology developed at Brookhaven National Laboratory, blockade paradigms similar to those used with propranolol and interaction studies referencing monoamine oxidase inhibitors characterized by Eli Lilly and Roche. Pharmacokinetic parameters reported in clinical pharmacology reports from Food and Drug Administration submissions include absorption, distribution, metabolism and elimination profiles comparable to related phenethylamine derivatives evaluated at Cleveland Clinic.

Medical and Research Applications

AMPT has been utilized in experimental therapeutics and research protocols investigating mood disorders, movement disorders, and neuroendocrine regulation at centers such as Kings College London, McGill University and Imperial College London. In research, AMPT challenge paradigms have been combined with neuroimaging modalities developed at Massachusetts Institute of Technology and Karolinska Institutet—including positron emission tomography techniques advanced by teams at University College London—to study catecholaminergic function in conditions investigated at Stanford University Medical Center and Mount Sinai Hospital. Clinical research comparing AMPT administration with treatment strategies involving electroconvulsive therapy, selective serotonin reuptake inhibitors trials at National Institute of Mental Health, and deep brain stimulation research at University of Florida has informed pathophysiological models of psychiatric and neurologic disorders. Pharmacodynamic challenge studies employing AMPT have been integrated into protocols developed by World Health Organization expert groups and regional consortia that include European Medicines Agency collaborators.

Legal Status and Safety

Regulatory consideration of AMPT has involved institutional review boards at Harvard Medical School, Oxford Clinical Trials Unit and regulatory authorities such as Food and Drug Administration and European Medicines Agency. Safety profiles reported in clinical trial archives from Beth Israel Deaconess Medical Center and multicenter studies coordinated by National Institutes of Health emphasize monitoring strategies analogous to those recommended in guidance from World Health Organization and Council for International Organizations of Medical Sciences. Adverse effect management protocols reference experience with agents from GlaxoSmithKline and AstraZeneca clinical programs; toxicity screening has followed standards promulgated by Organisation for Economic Co-operation and Development testing guidelines. Legal status for investigational use varies by jurisdiction and often requires institutional sponsorship and approvals similar to those required for experimental compounds evaluated at Nuffield Department of Medicine.

History and Development

The investigative history of AMPT is traceable through mid-20th century neuropharmacology literature alongside landmark studies by Walter B. Cannon-era laboratories and later work at National Institute of Mental Health and Institut National de la Santé et de la Recherche Médicale. Early experimental applications paralleled discovery efforts by Paul Greengard, Solomon Snyder, and contemporaries who established biochemical frameworks for neurotransmitter research at institutions including Rockefeller University and Columbia University. Subsequent clinical and translational research involving AMPT was conducted in collaborative networks that included Veterans Affairs Medical Center research programs, European clinical centers linked to European Research Council funding, and national initiatives coordinated by National Institutes of Health consortia. The compound remains a tool in mechanistic studies, with archival data and trial reports maintained in repositories associated with Wellcome Trust and academic libraries at University of Toronto.

Category:Chemical agents